Andreas Varkaris
Assistant Professor in Medicine Harvard Medical School
Dr. Varkaris is a physician scientist at the Mass General Cancer Center and a dedicated member of the Termeer Center for Targeted Therapies. His career has been marked by a dual commitment to direct patient care and pioneering translational research. Half of his efforts are devoted to administering early clinical trials of investigational agents targeting growth factor receptor signaling (FGFR2, PIK3CA and KRAS) , while the remaining time is focused on unraveling mechanisms of resistance to these agents and developing rational combination therapies that may benefit patients.
Seminars
Wednesday 9th September 2026
Is Perfect Selectivity Necessary? Rethinking KRAS Targeting in the Era of Resistance
1:00 pm
- Comparing mutant-selective versus isoform-selective KRAS inhibitors to evaluate trade-offs between biochemical precision and clinical durability
- Exploring how partial selectivity may extend duration of response and delay resistance in preclinical and clinical models
- Integrating frontline patient data to inform design of next-generation KRAS-targeted therapies that balance efficacy, safety, and real-world performance
